News

News


22 Apr 2014
The drug SQ109, developed by Sequella for the treatment of tuberculosis, blocks key biochemical pathways in bacteria, fungi, and parasites. The multiple targets of SQ109 have been determined by researchers at the University of Illinois Urbana-Champaign. The researchers also created analogs of SQ109...
26 Mar 2014
TB Alliance , an international non-profit whose mission is to develop better and more affordable drugs against tuberculosis, made three announcements on World TB Day demonstrating their commitment to combating childhood TB. Web portal for childhood TB On World TB Day, the TB Alliance in partnership...
11 Mar 2014
Vadim Makarov et. al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones . EMBO Molecular Medicine. 2014. March 1; 6(3). doi: 10.1002/emmm.201303575 A new antibiotic, labeled ‘PBTZ169’, has been shown to be effective against drug sensitive and MDR-tuberculosis...
6 Mar 2014
The European Medicines Agency (EMA) has recently approved Sirturo (bedaquiline) for conditional use in the European Union for adults suffering from pulmonary MDR-TB. The press release from Multimedia News Release can be found at: http://www.multivu.com/mnr/65014-sirturo-treatment-multi-drug-...
5 Mar 2014
Richard E. Lee et al. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux . Nature Medicine. 2014. March 6; 20(152). doi:10.1038/nm.3458 Abstract: Although the classical antibiotic spectinomycin is a potent bacterial protein synthesis inhibitor, poor...
25 Nov 2013
Source: European Medicines Agency http://www.ema.europa.eu On 21 November 2013, the Committee for Medicinal Products for Human Use (CHMP) recommended the granting of a conditional marketing authorisation for the medicinal product Deltyba for the treatment of lung infections due to multidrug-...
24 Oct 2013
Click to access report. This is the eighteenth global report on tuberculosis (TB) published by WHO in a series that started in 1997. It provides a comprehensive and up-to-date assessment of the TB epidemic and progress in implementing and financing TB prevention, care and control at global, regional...
9 Sep 2013
By: Shashank Gupta ( sgupta33@jhmi.edu ) In a significant finding for millions of TB patients, researchers have recently shown that adjunct chemotherapy with verapamil can accelerate tuberculosis treatment in mouse model. Investigators at Johns Hopkins School of Medicine have found that adding...
5 Sep 2013
You are invited to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2013 at Le Méridien Etoile in Paris, France, on Oct. 29th from 15:00 to 19:00. This meeting is held before the 44th Union World Conference on Lung Health (The Union). During the meeting we will review...
27 Aug 2013
Image Courtesy of Expert Medical Education This interactive workshop is held in conjunction with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The workshop is intended to provide clinicians, researchers, students and representatives from regulatory non-government...
29 Jul 2013
Source: Bloomberg http://www.bloomberg.com/news/2013-07-26/otsuka-s-drug-resistant-tb-treatment-fails-to-win-ema-nod.html Otsuka’s Drug-Resistant TB Treatment Fails to Win EMA Nod Otsuka Holdings Co. (4578) failed to win the backing of a European Medicines Agency panel for the Delamanid medicine...
16 Jul 2013
Source: http://www.bloomberg.com/article/2013-07-17/adCNbBPYeTyM.html Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc’s exclusive worldwide rights to develop and...
9 Jul 2013
Yesterday, the US National Public Radio posted online two insightful pieces on tuberculosis. What It Takes To Cure Drug-Resistant Tuberculosis Treating The ‘Body And Soul’ In A Russian TB Prison Please check it out and pass along.
8 Jul 2013
Enrollment has begun for a ground-breaking clinical program exploring the use of delamanid in paediatric multidrug-resistant tuberculosis (MDR-TB) . Otsuka is the first company to perform a trial among this population for regulatory approval. The programme will also evaluate the bioequivalence of a...
30 Jun 2013
Click here to access full report Source: Treatment Action Group The Tuberculosis Treatment Pipeline June 2013 Better than Ever Is Not Good Enough By Erica Lessem Introduction In December 2012, tuberculosis (TB) treatment reached a historic landmark with the first approval by a stringent regulatory...

Pages